SNS 301

Drug Profile

SNS 301

Alternative Names: HAAH vaccine; PAN-301; PAN-301-1; SNS-301

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacea Pharmaceuticals
  • Developer Sensei Biotherapeutics
  • Class Bacteriophages; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer
  • Clinical Phase Unknown Head and neck cancer; Myelodysplastic syndromes

Most Recent Events

  • 09 Oct 2018 Clinical trials in Myelodysplastic syndromes (Intradermal)
  • 05 Jun 2018 Sensei Biotherapeutics plans to initiate enrolment in a phase II efficacy trial for Prostate cancer by the end of 2018
  • 05 Jun 2018 Immunogenicity data from a phase I trial in Prostrate cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top